<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614011</url>
  </required_header>
  <id_info>
    <org_study_id>QVTP-39</org_study_id>
    <nct_id>NCT05614011</nct_id>
  </id_info>
  <brief_title>Q-POC SARS-CoV-2 Assay COVID-19 Clinical Evaluation</brief_title>
  <official_title>Q-POC SARS-CoV-2 Assay (Q27001) Clinical Performance Study Plan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QuantuMDx Group Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EDP Biotech</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PathAI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bright Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>QuantuMDx Group Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Q-POC SARS-CoV-2 moderate complexity PCR test performance evaluation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Q-POC SARS-CoV-2 Assay is a real-time PCR test intended for use on the Q-POC instrument&#xD;
      for the qualitative detection of nucleic acids from Severe Acute Respiratory Syndrome&#xD;
      Coronavirus 2 (SARS-CoV-2), in nasal mid-turbinate swabs (MTSW) obtained from individuals&#xD;
      suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories&#xD;
      certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C.&#xD;
      §263a, that meet requirements to perform high complexity or moderate complexity tests.&#xD;
&#xD;
      The Q-POC SARS-CoV-2 Assay is intended for use by laboratory personnel who have received&#xD;
      specific training on the use of the Q-POC SARS-CoV-2 Assay in conjunction with the Q-POC&#xD;
      instrument (Q29001).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2022</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a prospective clinical study enrolling adult patients with signs and symptoms that are consistent with SARS-CoV-2. Positive and negative specimens will be run on the Q-POC SARS-CoV-2 Assay in comparison with an FDA-approved reference standard to calculate both the positive percent agreement (PPA, or sensitivity) and the negative percent agreement (NPA, or specificity)</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive Percent Agreement</measure>
    <time_frame>3 months</time_frame>
    <description>The acceptance criteria for this study is Positive Percent Agreement (PPA) greater than or equal to 95% in a comparison between the Q-POC SARS-CoV-2 assay and the RT-PCR comparator test results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative Percent Agreement</measure>
    <time_frame>3 months</time_frame>
    <description>The acceptance criteria for this study is a Negative Percent Agreement (NPA) greater than or equal to 98% in a comparison between the Q-POC SARS-CoV-2 assay and the RT-PCR comparator test results.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Subjects 18+ years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A healthcare professional will take a sample per subject for the comparator test, following the manufacturer's (IFU) in one nostril. Mid-turbinate swab samples will be taken from the opposite nostril using Copan FLOQ Swabs and placed into MSwab buffer (Q14-116-P02), for the candidate test. In instances where opposite nostrils cannot be swabbed for both the comparator and the test under investigation, a 15-minute wait period to allow for viral reloading must occur between collecting both the comparator and the test samples on the same nostril.&#xD;
Comparator RT-PCR samples will be shipped overnight with ice packs and processed for testing within 48 hours of collection. Candidate test samples will tested as soon as possible following collection, however if time is required between specimen collection and testing, the samples must be stored at 2-8 °C for up to 24 hours. Test samples must also be stored at 2-8 °C whilst the Q-POC test is running.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>RT-PCR Test</intervention_name>
    <description>High sensitivity RT-PCR COVID-19 Test. A healthcare professional will take a sample per subject for the comparator test, following the manufacturer's Instructions For Use (IFU) in one nostril.</description>
    <arm_group_label>Subjects 18+ years of age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Real-time PCR Test</intervention_name>
    <description>Mid-turbinate nasal swab samples will be taken from the opposite nostril that was not swabbed for the comparator sample using Copan FLOQ swabs and placed into MSwab buffer. In instances where opposite nostrils cannot be swabbed for both the comparator and the candidate tests, a 15-minute waiting period to allow for viral reloading will occur before collecting the candidate test sample.</description>
    <arm_group_label>Subjects 18+ years of age</arm_group_label>
    <other_name>Q-POC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be over the age of 18 years.&#xD;
&#xD;
          -  Participants must present with symptoms indicative of SARS-CoV-2 infection, within 0-5&#xD;
             days of symptom onset.&#xD;
&#xD;
          -  Participants must have capacity to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is under the age of 18 years.&#xD;
&#xD;
          -  Participant does not have symptoms of SARS-CoV-2 infection.&#xD;
&#xD;
          -  Participant lacks capacity to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice Neilson</last_name>
    <role>Study Director</role>
    <affiliation>QuantuMDx Group Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Liggett, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EDP Biotech</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan Wilson, BS</last_name>
    <phone>8652996250</phone>
    <email>ryanwilson@edpbiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jason Liggett, PhD</last_name>
    <phone>8652996250</phone>
    <email>jasonliggett@edpbiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bright Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Mendez-Mulet, MD</last_name>
      <phone>786-870-5487</phone>
    </contact>
    <contact_backup>
      <last_name>Sukie Hernandez, MS</last_name>
      <phone>7868705487</phone>
      <email>shernandez@brclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>luis Mendez-Mulet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EDP Biotech</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37919</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Liggett, PhD</last_name>
      <phone>865-299-6250</phone>
      <email>jasonliggett@edpbiotech.com</email>
    </contact>
    <contact_backup>
      <last_name>Ryan Wilson</last_name>
      <phone>8652996250</phone>
      <email>ryanwilson@edpbiotech.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jason liggett, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PathAI</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anami Patel, PhD</last_name>
      <phone>901-526-1912</phone>
      <email>anami.patel@pathai.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Lasseter, PharmD</last_name>
      <phone>9015261912</phone>
      <email>jennifer.lasseter@pathai.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anami Patel, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 10, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>April 4, 2023</last_update_submitted>
  <last_update_submitted_qc>April 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

